8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 8, 2026·SEC
Material company update
Mar 3, 2026·SEC
STAAR Surgical Company(STAA)Earnings, Financials & Key Ratios
STAA•NASDAQ
Price updated Jun 19, 2026
AboutSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.Show more
- Revenue$239M-23.7%
- EBITDA-$37M-550.7%
- Net Income-$80M-298.1%
- EPS (Diluted)-1.62-295.1%
- Gross Margin76.19%-0.2%
- EBITDA Margin-15.54%-753.0%
- Operating Margin-19.19%-377.6%
- Net Margin-33.6%-421.9%
- ROE-21.7%-320.5%
STAA Key Insights
STAAR Surgical Company (STAA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when STAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STAA Price & Volume
STAAR Surgical Company (STAA) stock price & volume — 10-year historical chart
Loading chart...
STAA Growth Metrics
STAAR Surgical Company (STAA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12%
5 Years7.93%
3 Years-5.57%
TTM4.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM70.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM70.83%
Return on Capital
10 Years0.13%
5 Years3.87%
3 Years-2.29%
Last Year-11.04%
STAA Recent Earnings
STAAR Surgical Company (STAA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.38+600.8%
$0.05
Rev
$94M+18.8%
$79M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.20-211.1%
$0.18
Rev
$58M-22.9%
$75M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.46+155.6%
$0.18
Rev
$95M+25.4%
$76M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.07+87.5%
$0.56
Rev
$44M-50.3%
$89M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.38vs $0.05+600.8% | $94Mvs $79M+18.8% |
| Q2 2026 | Mar 3, 2026 | $0.20vs $0.18-211.1% | $58Mvs $75M-22.9% |
| Q4 2025 | Nov 5, 2025 | $0.46vs $0.18+155.6% | $95Mvs $76M+25.4% |
| Q3 2025 | Aug 6, 2025 | $0.07vs $0.56+87.5% | $44Mvs $89M-50.3% |
Based on last 12 quarters of dataView full earnings history →
STAA Peer Comparison
STAAR Surgical Company (STAA) competitors in Dental and vision care devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALGN | 13.04B | 182.08 | 32.23 | 0.9% | 10.5% | 10.7% | 0.03 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 TMDX | 2.72B | 78.79 | 16.18 | 37.13% | 27.04% | 41.92% | 0.99 | |
 EW | 50.37B | 87.36 | 47.74 | 11.55% | 17.64% | 10.35% | 0.07 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 IRTC | 3.44B | 104.65 | -75.29 | 26.24% | -3.53% | -20.6% | 4.79 |
Compare STAA vs Peers
STAAR Surgical Company (STAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STAA Income Statement
STAAR Surgical Company (STAA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Jan'20 | Jan'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 90.61M | 123.95M | 150.19M | 163.46M | 230.47M | 284.39M | 322.42M | 313.9M | 239.44M | 290.38M |
Revenue Growth % | 9.92% | 36.8% | 21.16% | 8.84% | 41% | 23.39% | 13.37% | -2.64% | -23.72% | 4.03% |
Cost of Goods Sold | 26.33M | 32.44M | 38.23M | 45.1M | 51.84M | 61.01M | 69.76M | 74.32M | 57.02M | 68.44M |
COGS % of Revenue | 29.06% | 26.17% | 25.46% | 27.59% | 22.49% | 21.45% | 21.64% | 23.68% | 23.81% | - |
Gross Profit | 64.28M▲ 0% | 91.51M▲ 42.4% | 111.95M▲ 22.3% | 118.36M▲ 5.7% | 178.64M▲ 50.9% | 223.38M▲ 25.0% | 252.65M▲ 13.1% | 239.58M▼ 5.2% | 182.42M▼ 23.9% | 221.94M▲ 0% |
Gross Margin % | 70.94% | 73.83% | 74.54% | 72.41% | 77.51% | 78.55% | 78.36% | 76.32% | 76.19% | 76.43% |
Gross Profit Growth % | 10.13% | 42.36% | 22.34% | 5.72% | 50.92% | 25.05% | 13.1% | -5.17% | -23.86% | - |
Operating Expenses | 67.91M | 84.92M | 100.1M | 111.59M | 145.3M | 179.58M | 224.55M | 252.19M | 228.37M | 226.94M |
OpEx % of Revenue | 74.95% | 68.51% | 66.65% | 68.27% | 63.04% | 63.15% | 69.65% | 80.34% | 95.37% | - |
Selling, General & Admin | 48.8M | 62.89M | 74.8M | 79.67M | 111.44M | 143.6M | 180.15M | 198.22M | 188.31M | 177.31M |
SG&A % of Revenue | 53.85% | 50.73% | 49.81% | 48.74% | 48.35% | 50.49% | 55.88% | 63.15% | 78.65% | - |
Research & Development | 19.12M | 22.03M | 25.3M | 31.92M | 33.86M | 35.98M | 44.4M | 53.97M | 40.05M | 38.43M |
R&D % of Revenue | 21.1% | 17.77% | 16.84% | 19.53% | 14.69% | 12.65% | 13.77% | 17.19% | 16.73% | - |
Other Operating Expenses | 628K | 715K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M |
Operating Income | -3.63M▲ 0% | 6.59M▲ 281.6% | 11.85M▲ 79.7% | 6.77M▼ 42.9% | 33.34M▲ 392.5% | 43.8M▲ 31.4% | 28.1M▼ 35.9% | -12.61M▼ 144.9% | -45.95M▼ 264.3% | -5.01M▲ 0% |
Operating Margin % | -4.01% | 5.32% | 7.89% | 4.14% | 14.47% | 15.4% | 8.71% | -4.02% | -19.19% | -1.72% |
Operating Income Growth % | 71.31% | 281.63% | 79.71% | -42.89% | 392.52% | 31.38% | -35.85% | -144.88% | -264.33% | - |
EBITDA | -277K | 9.06M | 15.55M | 9.86M | 36.98M | 48.31M | 33.22M | -5.72M | -37.22M | 3.6M |
EBITDA Margin % | -0.31% | 7.31% | 10.35% | 6.03% | 16.05% | 16.99% | 10.3% | -1.82% | -15.54% | 1.24% |
EBITDA Growth % | 97.16% | 3370.4% | 71.66% | -36.57% | 274.91% | 30.64% | -31.24% | -117.22% | -550.66% | 106.02% |
D&A (Non-Cash Add-back) | 3.35M | 2.46M | 3.7M | 3.1M | 3.64M | 4.51M | 5.12M | 6.89M | 8.73M | 8.6M |
EBIT | -3.63M | 6.59M | 11.85M | 6.77M | 33.34M | 43.8M | 28.1M | -12.61M | -45.95M | 6.19M |
Net Interest Income | -112K | 165K | 988K | 238K | -38K | 2.45M | 6.99M | 5.91M | 4.59M | 4.13M |
Interest Income | 0 | 165K | 988K | 238K | - | 2.45M | 6.99M | 5.91M | 4.59M | 4.13M |
Interest Expense | 112K | 0 | 0 | 0 | 38K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.33M | 44K | 1.17M | 1.5M | -2.04M | 1.75M | 5.6M | 3.56M | -36.32M | -14.55M |
Pretax Income | -2.3M▲ 0% | 6.64M▲ 389.2% | 13.03M▲ 96.2% | 8.27M▼ 36.5% | 31.3M▲ 278.7% | 45.55M▲ 45.5% | 33.7M▼ 26.0% | -9.05M▼ 126.9% | -82.26M▼ 808.8% | -19.56M▲ 0% |
Pretax Margin % | -2.53% | 5.36% | 8.67% | 5.06% | 13.58% | 16.02% | 10.45% | -2.88% | -34.36% | -6.74% |
Income Tax | -157K | 1.67M | -1.02M | 2.35M | 3.79M | 5.89M | 12.35M | 11.16M | -1.81M | 1.47M |
Effective Tax Rate % | 6.84% | 25.17% | -7.85% | 28.47% | 12.12% | 12.92% | 36.65% | -123.24% | 2.21% | -7.53% |
Net Income | -2.14M▲ 0% | 4.97M▲ 332.3% | 14.05M▲ 182.8% | 5.91M▼ 57.9% | 27.51M▲ 365.3% | 39.66M▲ 44.2% | 21.35M▼ 46.2% | -20.21M▼ 194.7% | -80.45M▼ 298.1% | -21.03M▲ 0% |
Net Margin % | -2.36% | 4.01% | 9.35% | 3.62% | 11.94% | 13.95% | 6.62% | -6.44% | -33.6% | -7.24% |
Net Income Growth % | 82.36% | 332.26% | 182.77% | -57.91% | 365.26% | 44.18% | -46.18% | -194.66% | -298.1% | 70.41% |
Net Income (Continuing) | -2.14M | 4.97M | 14.05M | 5.91M | 27.51M | 39.66M | 21.35M | -20.21M | -80.45M | -21.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.05▲ 0% | 0.11▲ 310.7% | 0.30▲ 172.7% | 0.12▼ 60.0% | 0.50▲ 316.7% | 0.80▲ 60.0% | 0.43▼ 46.3% | -0.41▼ 195.3% | -1.62▼ 295.1% | -0.41▲ 0% |
EPS Growth % | 82.6% | 310.73% | 172.73% | -60% | 316.67% | 60% | -46.25% | -195.35% | -295.12% | 70.83% |
EPS (Basic) | -0.05 | 0.11 | 0.32 | 0.13 | 0.52 | 0.83 | 0.44 | -0.41 | -1.62 | - |
Diluted Shares Outstanding | 41M | 45.26M | 46.9M | 47.95M | 49.46M | 49.38M | 49.43M | 49.13M | 49.57M | 50.9M |
Basic Shares Outstanding | 41M | 45.16M | 44.49M | 45.6M | 47.21M | 47.99M | 48.52M | 49.13M | 49.57M | 49.91M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
STAA Balance Sheet
STAAR Surgical Company (STAA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Jan'20 | Jan'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 53.89M | 151.57M | 174.67M | 216.42M | 271.41M | 311.72M | 365.27M | 367.94M | 311.55M | 312.4M |
Cash & Short-Term Investments | 18.52M | 103.88M | 119.97M | 152.45M | 199.71M | 211.64M | 220.73M | 230.49M | 187.54M | 163.89M |
Cash Only | 18.52M | 103.88M | 119.97M | 152.45M | 199.71M | 86.48M | 183.04M | 144.16M | 153.15M | 131.86M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 125.16M | 37.69M | 86.33M | 34.39M | 32.02M |
Accounts Receivable | 17.85M | 25.95M | 32.58M | 35.23M | 46.56M | 65.97M | 97.98M | 79.26M | 54.61M | 85.69M |
Days Sales Outstanding | 71.92 | 76.4 | 79.19 | 78.67 | 73.73 | 84.67 | 110.92 | 92.16 | 83.24 | 75.72 |
Inventory | 13.31M | 16.7M | 17.14M | 18.11M | 17.27M | 24.16M | 35.13M | 43.3M | 55.5M | 49.78M |
Days Inventory Outstanding | 184.5 | 187.92 | 163.66 | 146.58 | 121.64 | 144.55 | 183.8 | 212.68 | 355.23 | 282.25 |
Other Current Assets | 1.83M | 2.07M | 453K | 4.53M | 636K | 811K | 6.98M | 980K | 8.04M | 13.03M |
Total Non-Current Assets | 14.04M | 15.77M | 32.86M | 41M | 74.37M | 107.09M | 123.42M | 141.58M | 150.07M | 138.72M |
Property, Plant & Equipment | 9.78M | 11.45M | 25.62M | 33.39M | 67.73M | 81.53M | 101.41M | 121.78M | 102.93M | 100.31M |
Fixed Asset Turnover | 9.27x | 10.82x | 5.86x | 4.90x | 3.40x | 3.49x | 3.18x | 2.58x | 2.33x | 2.80x |
Goodwill | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M |
Intangible Assets | 271K | 243K | 296K | 270K | 218K | 173K | 0 | 0 | 30.7M | 0 |
Long-Term Investments | 121K | 122K | 0 | 0 | 0 | 13.9M | 11.7M | 0 | 0 | 0 |
Other Non-Current Assets | 846K | 887K | 751K | 608K | 822K | 957K | 3.34M | 17.23M | 1.35M | 35.54M |
Total Assets | 67.93M▲ 0% | 167.34M▲ 146.3% | 207.52M▲ 24.0% | 257.42M▲ 24.0% | 345.78M▲ 34.3% | 418.82M▲ 21.1% | 488.69M▲ 16.7% | 509.52M▲ 4.3% | 461.62M▼ 9.4% | 451.12M▲ 0% |
Asset Turnover | 1.33x | 0.74x | 0.72x | 0.64x | 0.67x | 0.68x | 0.66x | 0.62x | 0.52x | 0.64x |
Asset Growth % | 3.8% | 146.33% | 24.01% | 24.04% | 34.33% | 21.12% | 16.68% | 4.26% | -9.4% | -40.5% |
Total Current Liabilities | 19.09M | 27.73M | 34.48M | 41.24M | 48.8M | 51.72M | 65.04M | 70.31M | 68.5M | 60.99M |
Accounts Payable | 6.03M | 6.52M | 8.05M | 2.82M | 8.7M | 11.58M | 13.56M | 16.7M | 11.57M | 8.7M |
Days Payables Outstanding | 83.63 | 73.4 | 76.86 | 22.8 | 61.25 | 69.26 | 70.93 | 82.04 | 74.09 | 55.73 |
Short-Term Debt | 4.44M | 3.78M | 1.83M | 1.38M | 0 | 0 | 0 | 0 | 0 | 6.1M |
Deferred Revenue (Current) | 0 | 2.1M | 0 | 4.53M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.86M | 5.99M | 11.09M | 9.07M | 22.41M | 21.74M | 21.43M | 24.28M | 49.75M | 46.2M |
Current Ratio | 2.82x | 5.47x | 5.07x | 5.25x | 5.56x | 6.03x | 5.62x | 5.23x | 4.55x | 5.12x |
Quick Ratio | 2.13x | 4.86x | 4.57x | 4.81x | 5.21x | 5.56x | 5.08x | 4.62x | 3.74x | 4.31x |
Cash Conversion Cycle | 172.79 | 190.93 | 165.99 | 202.45 | 134.12 | 159.97 | 223.79 | 222.81 | 364.39 | 302.25 |
Total Non-Current Liabilities | 5.91M | 7.18M | 13.16M | 18.96M | 38.42M | 30.99M | 37.7M | 41.88M | 48.93M | 37.76M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 531K | 459K | 4.45M | 6.58M | 28.65M | 27.35M | 31.47M | 34.81M | 32.48M | 132.89M |
Deferred Tax Liabilities | 350K | 1.02M | 658K | 222K | 811K | 1.49M | 1.08M | 297K | 9.94M | 9.94M |
Other Non-Current Liabilities | 5.03M | 5.7M | 8.05M | 12.16M | 8.96M | 2.15M | 5.16M | 6.78M | 6.42M | 6.48M |
Total Liabilities | 25M | 34.91M | 47.64M | 60.19M | 87.22M | 82.71M | 102.74M | 112.19M | 117.44M | 98.75M |
Total Debt | 6.25M | 5.34M | 9.54M | 10.8M | 32.06M | 31.04M | 35.83M | 38.74M | 38.35M | 37.29M |
Net Debt | -12.27M | -98.54M | -110.43M | -141.65M | -167.65M | -55.44M | -147.2M | -105.42M | -114.8M | -94.57M |
Debt / Equity | 0.15x | 0.04x | 0.06x | 0.05x | 0.12x | 0.09x | 0.09x | 0.10x | 0.11x | 0.11x |
Debt / EBITDA | - | 0.59x | 0.61x | 1.09x | 0.87x | 0.64x | 1.08x | - | - | 10.37x |
Net Debt / EBITDA | - | -10.88x | -7.10x | -14.36x | -4.53x | -1.15x | -4.43x | - | - | -26.30x |
Interest Coverage | -32.42x | - | - | - | 877.34x | - | - | - | - | - |
Total Equity | 42.94M▲ 0% | 132.43M▲ 208.4% | 159.88M▲ 20.7% | 197.22M▲ 23.4% | 258.56M▲ 31.1% | 336.11M▲ 30.0% | 385.95M▲ 14.8% | 397.33M▲ 2.9% | 344.18M▼ 13.4% | 352.37M▲ 0% |
Equity Growth % | 13.27% | 208.43% | 20.73% | 23.35% | 31.1% | 29.99% | 14.83% | 2.95% | -13.38% | -47.79% |
Book Value per Share | 1.05 | 2.93 | 3.41 | 4.11 | 5.23 | 6.81 | 7.81 | 8.09 | 6.94 | 6.92 |
Total Shareholders' Equity | 42.94M | 132.43M | 159.88M | 197.22M | 258.56M | 336.11M | 385.95M | 397.33M | 344.18M | 352.37M |
Common Stock | 414K | 442K | 448K | 464K | 477K | 482K | 488K | 493K | 498K | 502K |
Retained Earnings | -161.25M | -156.28M | -141.8M | -135.89M | -111.39M | -68.72M | -47.37M | -67.58M | -148.02M | -142.82M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.46M | -6.46M |
Accumulated OCI | -1.15M | -1.32M | -3.05M | -5.54M | -4.05M | 156K | -4.11M | -7.03M | -6.51M | -6.78M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STAA Cash Flow Statement
STAAR Surgical Company (STAA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Jan'20 | Jan'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 2.85M | 12.77M | 25.8M | 20.95M | 43.96M | 35.72M | 14.59M | 15.72M | -34.23M | -50.19M |
Operating CF Margin % | 3.15% | 10.3% | 17.18% | 12.82% | 19.07% | 12.56% | 4.53% | 5.01% | -14.3% | - |
Operating CF Growth % | 171.97% | 347.49% | 102.04% | -18.78% | 109.83% | -18.76% | -59.14% | 7.75% | -317.68% | -1179.81% |
Net Income | -2.14M | 4.97M | 14.05M | 5.91M | 27.51M | 39.01M | 21.35M | -20.21M | -80.45M | -21.03M |
Depreciation & Amortization | 3.35M | 2.46M | 3.7M | 3.1M | 3.64M | 4.51M | 5.12M | 6.89M | 8.32M | 8.6M |
Stock-Based Compensation | 3.16M | 6.76M | 10.55M | 12.15M | 14.61M | 20.37M | 23.52M | 27.21M | 30.59M | 24.57M |
Deferred Taxes | -547K | 441K | -3.48M | -849K | -1.51M | -1.34M | 3.26M | 3.59M | -2.92M | 923K |
Other Non-Cash Items | 3.01M | 2.62M | 2.23M | 3.41M | 2.11M | 2.3M | 2.18M | 3.64M | 26.55M | 25.16M |
Working Capital Changes | -3.99M | -4.49M | -1.25M | -2.76M | -2.39M | -29.13M | -40.84M | -5.4M | -16.33M | -88.42M |
Change in Receivables | -1.86M | -6.04M | -4.5M | -3.97M | -8.87M | -19.6M | -32.76M | 16.49K | 27.83M | -42.26M |
Change in Inventory | 312K | -4.19M | -950K | -1.39M | 66K | -7.94M | -14.36M | -10K | -16.98M | -6.59M |
Change in Payables | -2.5M | 243K | 1.08M | -1.2M | 108K | 1.8M | -701K | 75 | -5.51M | -2.5M |
Cash from Investing | -1.05M | -2.25M | -10.18M | -8.4M | -13.64M | -156.38M | 74.35M | -59.22M | 46.34M | 13.13M |
Capital Expenditures | -1.05M | -2.25M | -10.1M | -8.4M | -13.64M | -18.11M | -18.19M | -23.39M | -5.82M | -4.79M |
CapEx % of Revenue | 1.15% | 1.81% | 6.72% | 5.14% | 5.92% | 6.37% | 5.64% | 7.45% | 2.43% | 1.65% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 138.27M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -83K | 0 | 0 | -138.27M | 0 | 0 | 198K | 0 |
Cash from Financing | 2.44M | 74.64M | 149K | 19.57M | 17.79M | 8.3M | 7.42M | 5.72M | -4.55M | -5.3M |
Debt Issued (Net) | -1.3M | -1.91M | -3.31M | -1.08M | -1.65M | -126K | -161K | -165K | -42K | 0 |
Equity Issued (Net) | -234K | -54K | 2K | 1K | 1K | 1K | -2.1M | -1.5M | -2.99M | -8.19M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -234K | -54K | 0 | 0 | 0 | 0 | -2.1M | -1.5M | -6.46M | -8.49M |
Other Financing | 3.97M | 76.6M | 3.46M | 20.65M | 19.44M | 8.42M | 9.67M | 7.39M | -1.52M | 2.89M |
Net Change in Cash | 4.52M▲ 0% | 85.36M▲ 1787.2% | 15.97M▼ 81.3% | 32.48M▲ 103.4% | 47.25M▲ 45.5% | -113.23M▼ 339.6% | 96.56M▲ 185.3% | -38.88M▼ 140.3% | 8.99M▲ 123.1% | -41.25M▲ 0% |
Free Cash Flow | 1.81M▲ 0% | 10.52M▲ 482.3% | 15.62M▲ 48.4% | 12.55M▼ 19.7% | 30.32M▲ 141.6% | 17.61M▼ 41.9% | -3.59M▼ 120.4% | -7.67M▼ 113.4% | -40.05M▼ 422.2% | -54.99M▲ 0% |
FCF Margin % | 1.99% | 8.49% | 10.4% | 7.68% | 13.15% | 6.19% | -1.11% | -2.44% | -16.73% | -18.94% |
FCF Growth % | 183.81% | 482.29% | 48.42% | -19.66% | 141.63% | -41.92% | -120.41% | -113.38% | -422.23% | -301.94% |
FCF per Share | 0.04 | 0.23 | 0.33 | 0.26 | 0.61 | 0.36 | -0.07 | -0.16 | -0.81 | -1.08 |
FCF Conversion (FCF/Net Income) | -1.33x | 2.57x | 1.84x | 3.54x | 1.60x | 0.90x | 0.68x | -0.78x | 0.43x | 2.61x |
Interest Paid | 0 | 0 | 0 | 0 | 75K | 52K | 75K | 87K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 7.47M | 6.63M | 2.84M | 10.98M | 0 | 0 |
STAA Key Ratios
STAAR Surgical Company (STAA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -5.29% | 5.67% | 9.61% | 3.31% | 12.07% | 13.34% | 5.91% | -5.16% | -21.7% | -6.07% |
Return on Invested Capital (ROIC) | -8.87% | 15.33% | 21.33% | 9.67% | 34.14% | 17.68% | 8.11% | -3.56% | -13.22% | -1.64% |
Gross Margin | 70.94% | 73.83% | 74.54% | 72.41% | 77.51% | 78.55% | 78.36% | 76.32% | 76.19% | 76.43% |
Net Margin | -2.36% | 4.01% | 9.35% | 3.62% | 11.94% | 13.95% | 6.62% | -6.44% | -33.6% | -7.24% |
Debt / Equity | 0.15x | 0.04x | 0.06x | 0.05x | 0.12x | 0.09x | 0.09x | 0.10x | 0.11x | 0.11x |
Interest Coverage | -32.42x | - | - | - | 877.34x | - | - | - | - | - |
FCF Conversion | -1.33x | 2.57x | 1.84x | 3.54x | 1.60x | 0.90x | 0.68x | -0.78x | 0.43x | 2.61x |
Revenue Growth | 9.92% | 36.8% | 21.16% | 8.84% | 41% | 23.39% | 13.37% | -2.64% | -23.72% | 4.03% |
Related:STAA Dividend History·STAA Revenue History·STAA Price History·STAA P/E History·STAA Financial Ratios·STAA Institutional Holders
STAA SEC Filings & Documents
STAAR Surgical Company (STAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
STAA Frequently Asked Questions
STAAR Surgical Company (STAA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
STAAR Surgical Company (STAA) reported $290.4M in revenue for fiscal year 2025. This represents a 588% increase from $42.2M in 1996.
STAAR Surgical Company (STAA) saw revenue decline by 23.7% over the past year.
STAAR Surgical Company (STAA) reported a net loss of $21.0M for fiscal year 2025.
Dividend & Returns
STAAR Surgical Company (STAA) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
STAAR Surgical Company (STAA) had negative free cash flow of $55.0M in fiscal year 2025, likely due to heavy capital investments.